HOLX - Hologic KKR-backed Ajax Health develop lung cancer detection platform

2023-11-30 08:20:51 ET

Medtech firm Hologic ( NASDAQ: HOLX ) and KKR-backed Ajax Health have developed a new platform to detect lung cancer .

Named Maverix Medical and managed by Ajax Health , the platform will develop and acquire innovative technologies and commercial operations within the lung cancer disease category, which is the leading cause of cancer deaths worldwide.

KKR and Ajax Health will contribute existing portfolio company Serpex Medical to the platform. Serpex develops steerable technology to target lung tissue for biopsy or delivery of therapy.

"This strategic partnership strongly aligns with our leadership in diagnostic innovation and early cancer detection. Together with Ajax and KKR, we are excited to partner on a platform that leverages our strengths and expertise to target new disease categories, such as lung cancer, and that will allow us to continue to enable healthier lives everywhere, every day," said Steve MacMillan, chairman, president and chief executive officer of Hologic ( HOLX ).

KKR is investing in Maverix as part of its Health Care Strategic Growth strategy. Additional terms of the transaction were not disclosed.

More on Hologic

• Hologic: Navigating The Covid Cliff
• Hologic, Inc. (HOLX) Q4 2023 Earnings Call Transcript
• Hologic: Post-Covid World Proving To Be A Nuisance On Profitability (Rating Downgrade)
• Hologic gains as Q4 results cite ex-COVID growth
• Hologic Non-GAAP EPS of $0.89 beats by $0.05, revenue of $945.3M beats by $5.39M

For further details see: